ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1789

Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Abstract Number: 1733

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Abstract Number: 1253

Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
Abstract Number: 2092

Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
Abstract Number: 0150

Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
Abstract Number: 2110

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Abstract Number: 2127

Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Abstract Number: 1850

Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Abstract Number: 0509

Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Abstract Number: 0507

Gut Microbe Metabolite Short-Chain Fatty Acids May Associate with Development of Respiratory Involvement in Patients with Relapsing Polychondritis
Abstract Number: 2181

Gut Microbe-derived Short-Chain Fatty Acids Regulate Arthritis and Myositis During Chikungunya Virus Infection
Abstract Number: 1148

GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA
Abstract Number: 2093

Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
Abstract Number: 1381

Health Related Quality of Life in Children with Systemic Lupus Erythematosus
Abstract Number: 0058

Health System Improvement in Inpatient ANA and Serologic Test Utilization

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].